Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms

A. Galli, E. Ceni, David Crabb, T. Mello, R. Salzano, C. Grappone, S. Milani, E. Surrenti, C. Surrenti, A. Casini

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background/Aims: Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of some epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferators activated receptor γ (PPARγ) the mechanism by which TZD exert their anticancer effect is currently unclear. Furthermore, the effect of TZD on local motility and metastatic potential of cancer cells is unknown. The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma. Methods: Expression of PPARγ in human pancreatic adenocarcinomas and pancreatic carcinoma cell lines was measured by reverse transcription polymerase chain reaction and confirmed by western blot analysis. PPARγ activity was evaluated by transient reporter gene assay. Invasion assay was performed in modified Boyden chambers. Gelatinolytic and fibrinolytic activity were evaluated by gel zymography. Results: TZD inhibited pancreatic cancer cells' invasiveness, affecting gelatinolytic and fibrinolytic activity with a mechanism independent of PPARγ activation and involving MMP-2 and PAI-1 expression. Conclusion: TZD treatment in pancreatic cancer cells has potent inhibitory effects on growth and invasiveness suggesting that these drugs may have application for prevention and treatment of pancreatic cancer in humans.

Original languageEnglish
Pages (from-to)1688-1697
Number of pages10
JournalGut
Volume53
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Thiazolidinediones
Peroxisome Proliferator-Activated Receptors
Pancreatic Neoplasms
Hypoglycemic Agents
rosiglitazone
pioglitazone
Adenocarcinoma
Cell Line
Plasminogen Activator Inhibitor 1
Therapeutic Uses
Growth
Matrix Metalloproteinases
Reporter Genes
Pharmaceutical Preparations
Reverse Transcription
Neoplasms
Western Blotting
Gels
Epithelial Cells
Ligands

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms. / Galli, A.; Ceni, E.; Crabb, David; Mello, T.; Salzano, R.; Grappone, C.; Milani, S.; Surrenti, E.; Surrenti, C.; Casini, A.

In: Gut, Vol. 53, No. 11, 11.2004, p. 1688-1697.

Research output: Contribution to journalArticle

Galli, A, Ceni, E, Crabb, D, Mello, T, Salzano, R, Grappone, C, Milani, S, Surrenti, E, Surrenti, C & Casini, A 2004, 'Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms', Gut, vol. 53, no. 11, pp. 1688-1697. https://doi.org/10.1136/gut.2003.031997
Galli, A. ; Ceni, E. ; Crabb, David ; Mello, T. ; Salzano, R. ; Grappone, C. ; Milani, S. ; Surrenti, E. ; Surrenti, C. ; Casini, A. / Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms. In: Gut. 2004 ; Vol. 53, No. 11. pp. 1688-1697.
@article{09a7d7cf0ffe4f9bb79efa19f993bdec,
title = "Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms",
abstract = "Background/Aims: Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of some epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferators activated receptor γ (PPARγ) the mechanism by which TZD exert their anticancer effect is currently unclear. Furthermore, the effect of TZD on local motility and metastatic potential of cancer cells is unknown. The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma. Methods: Expression of PPARγ in human pancreatic adenocarcinomas and pancreatic carcinoma cell lines was measured by reverse transcription polymerase chain reaction and confirmed by western blot analysis. PPARγ activity was evaluated by transient reporter gene assay. Invasion assay was performed in modified Boyden chambers. Gelatinolytic and fibrinolytic activity were evaluated by gel zymography. Results: TZD inhibited pancreatic cancer cells' invasiveness, affecting gelatinolytic and fibrinolytic activity with a mechanism independent of PPARγ activation and involving MMP-2 and PAI-1 expression. Conclusion: TZD treatment in pancreatic cancer cells has potent inhibitory effects on growth and invasiveness suggesting that these drugs may have application for prevention and treatment of pancreatic cancer in humans.",
author = "A. Galli and E. Ceni and David Crabb and T. Mello and R. Salzano and C. Grappone and S. Milani and E. Surrenti and C. Surrenti and A. Casini",
year = "2004",
month = "11",
doi = "10.1136/gut.2003.031997",
language = "English",
volume = "53",
pages = "1688--1697",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms

AU - Galli, A.

AU - Ceni, E.

AU - Crabb, David

AU - Mello, T.

AU - Salzano, R.

AU - Grappone, C.

AU - Milani, S.

AU - Surrenti, E.

AU - Surrenti, C.

AU - Casini, A.

PY - 2004/11

Y1 - 2004/11

N2 - Background/Aims: Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of some epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferators activated receptor γ (PPARγ) the mechanism by which TZD exert their anticancer effect is currently unclear. Furthermore, the effect of TZD on local motility and metastatic potential of cancer cells is unknown. The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma. Methods: Expression of PPARγ in human pancreatic adenocarcinomas and pancreatic carcinoma cell lines was measured by reverse transcription polymerase chain reaction and confirmed by western blot analysis. PPARγ activity was evaluated by transient reporter gene assay. Invasion assay was performed in modified Boyden chambers. Gelatinolytic and fibrinolytic activity were evaluated by gel zymography. Results: TZD inhibited pancreatic cancer cells' invasiveness, affecting gelatinolytic and fibrinolytic activity with a mechanism independent of PPARγ activation and involving MMP-2 and PAI-1 expression. Conclusion: TZD treatment in pancreatic cancer cells has potent inhibitory effects on growth and invasiveness suggesting that these drugs may have application for prevention and treatment of pancreatic cancer in humans.

AB - Background/Aims: Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of some epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferators activated receptor γ (PPARγ) the mechanism by which TZD exert their anticancer effect is currently unclear. Furthermore, the effect of TZD on local motility and metastatic potential of cancer cells is unknown. The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma. Methods: Expression of PPARγ in human pancreatic adenocarcinomas and pancreatic carcinoma cell lines was measured by reverse transcription polymerase chain reaction and confirmed by western blot analysis. PPARγ activity was evaluated by transient reporter gene assay. Invasion assay was performed in modified Boyden chambers. Gelatinolytic and fibrinolytic activity were evaluated by gel zymography. Results: TZD inhibited pancreatic cancer cells' invasiveness, affecting gelatinolytic and fibrinolytic activity with a mechanism independent of PPARγ activation and involving MMP-2 and PAI-1 expression. Conclusion: TZD treatment in pancreatic cancer cells has potent inhibitory effects on growth and invasiveness suggesting that these drugs may have application for prevention and treatment of pancreatic cancer in humans.

UR - http://www.scopus.com/inward/record.url?scp=7244234089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244234089&partnerID=8YFLogxK

U2 - 10.1136/gut.2003.031997

DO - 10.1136/gut.2003.031997

M3 - Article

VL - 53

SP - 1688

EP - 1697

JO - Gut

JF - Gut

SN - 0017-5749

IS - 11

ER -